Our study aims are 1) to characterize and describe the clinical characteristics of patients with ILD and a positive anti-Ro52, 2) to compare the presenting phenotypes of patients with anti-Ro52 alone versus in combination with a positive myositis-specific autoantibody, and 3) to identify prognostic predictors associated with ILD progression or death. The gene discussed is TRIM21; the disease is myositis disease.